Achievements

Some of ZEM Life's Achievements

The company has made considerable progress since the original idea was developed in 2021. The following list entails some of the most critical achievements to date:

ZEM Life Device idea created through difficulty from an unlikely event – October 2021
ZEM Life engineering team determined that the functionality of the device idea could be feasible and implemented – December 2021
ZEM Life Group agreed to share technology with the world for humanitarian reasons and Palms 23 Foundation nonprofit; received commitment of near-term development capital and donations – December 2021
ZEM Life US provisional application number 63-294,184 filed – December 28, 2021
Completed full patent along with engineering feasibility and design – November 2022
ZEM Life full patent application filed US18/089,656 – December 28, 2022
Secured CUBE Medical Innovations for development of device to meet FDA requirements – April 2023
Received full patent pending status US20230201463A1 – June 29, 2023
Secured Eminence Clinical Research for FDA assistance – July 2023
Filed Designation Request for Breakthrough Device with FDA – September 2023
Secured crowdfunding offering with Reg D company – October 2023
Filed corporation paperwork in Delaware – December 2023
Concluded high-level plan for FDA, working with both Eminence Clinical Research and CUBE Medical Innovations – January 2024
Partnered with Grant Engine for assistance in securing grant capital for the production of the Narcan band – January 2024
Engaged all Executive Directors at hourly pay rate of minimum wage – March 2024
Secured Rialto Markets as a broker-dealer – March 2024
Filed SBIR Phase I application – April 2024
Filed additional patent addendums – April 2024
Completed plastic dummy watch to mimic smallest possible size – May 2024
Completed SEC and Form C crowdfunding offering agreements – June 2024
Partnered with Grantify for assistance in securing grant capital for the cardiac arrest cartridge – June 2024